Markers for Guillain-Barré syndrome with poor prognosis: a multi-center study

Yuko Yamagishi; Hidekazu Suzuki; Masahiro Sonoo; Satoshi Kuwabara; Takanori Yokota; Kyoichi Nomura; Atsuro Chiba; Ryuji Kaji; Takashi Kanda; Kenichi Kaida; Shu Ichi Ikeda; Tatsuro Mutoh; Ryo Yamasaki; Hiroshi Takashima; Makoto Matsui; Kazutoshi Nishiyama; Gen Sobue; Susumu Kusunoki

doi:10.1111/jns.12234

Markers for Guillain-Barré syndrome with poor prognosis: a multi-center study

Yuko Yamagishi, Hidekazu Suzuki, Masahiro Sonoo, Satoshi Kuwabara, Takanori Yokota, Kyoichi Nomura, Atsuro Chiba, Ryuji Kaji, Takashi Kanda, Kenichi Kaida, Shu Ichi Ikeda, Tatsuro Mutoh, Ryo Yamasaki, Hiroshi Takashima, Makoto Matsui, Kazutoshi Nishiyama, Gen Sobue, Susumu Kusunoki

Central Japan International Airport Clinic

Research output: Contribution to journal › Article › peer-review

54 Citations (Scopus)

Abstract

Guillain-Barré syndrome (GBS) is an acute monophasic neuropathy. Prognostic tools include the modified Erasmus GBS outcome score (mEGOS), Erasmus GBS respiratory insufficiency score (EGRIS), and the increase in serum IgG levels (ΔIgG) 2 weeks after intravenous immunoglobulin (IVIg) treatment. Given that proportions of GBS subtypes differ between Western countries and Japan, the usefulness of these tools in Japan or other countries remains unknown. We enrolled 177 Japanese patients with GBS from 15 university hospitals and retrospectively obtained mEGOS and EGRIS for all and ΔIgG status for 79 of them. High mEGOS scores on admission or on day 7 were significantly associated with poorer outcomes (unable to walk independently at 6 months). High EGRIS scores (≥5 points) were associated with an increased risk for mechanical ventilation. Patients with ΔIgG <1,108 mg/dl had significantly poorer outcomes. We suggest that mEGOS, EGRIS, and ΔIgG in GBS are clinically relevant in Japan.

Original language	English
Pages (from-to)	433-439
Number of pages	7
Journal	Journal of the Peripheral Nervous System
Volume	22
Issue number	4
DOIs	https://doi.org/10.1111/jns.12234
Publication status	Published - 12-2017

All Science Journal Classification (ASJC) codes

General Neuroscience
Clinical Neurology

Access to Document

10.1111/jns.12234

Cite this

Yamagishi, Y., Suzuki, H., Sonoo, M., Kuwabara, S., Yokota, T., Nomura, K., Chiba, A., Kaji, R., Kanda, T., Kaida, K., Ikeda, S. I., Mutoh, T., Yamasaki, R., Takashima, H., Matsui, M., Nishiyama, K., Sobue, G., & Kusunoki, S. (2017). Markers for Guillain-Barré syndrome with poor prognosis: a multi-center study. Journal of the Peripheral Nervous System, 22(4), 433-439. https://doi.org/10.1111/jns.12234

@article{715ec66c45ea4e809144988c783b58e0,

title = "Markers for Guillain-Barr{\'e} syndrome with poor prognosis: a multi-center study",

abstract = "Guillain-Barr{\'e} syndrome (GBS) is an acute monophasic neuropathy. Prognostic tools include the modified Erasmus GBS outcome score (mEGOS), Erasmus GBS respiratory insufficiency score (EGRIS), and the increase in serum IgG levels (ΔIgG) 2 weeks after intravenous immunoglobulin (IVIg) treatment. Given that proportions of GBS subtypes differ between Western countries and Japan, the usefulness of these tools in Japan or other countries remains unknown. We enrolled 177 Japanese patients with GBS from 15 university hospitals and retrospectively obtained mEGOS and EGRIS for all and ΔIgG status for 79 of them. High mEGOS scores on admission or on day 7 were significantly associated with poorer outcomes (unable to walk independently at 6 months). High EGRIS scores (≥5 points) were associated with an increased risk for mechanical ventilation. Patients with ΔIgG <1,108 mg/dl had significantly poorer outcomes. We suggest that mEGOS, EGRIS, and ΔIgG in GBS are clinically relevant in Japan.",

keywords = "EGRIS, Guillain-Barr{\'e} syndrome, mEGOS, prognostic marker",

author = "Yuko Yamagishi and Hidekazu Suzuki and Masahiro Sonoo and Satoshi Kuwabara and Takanori Yokota and Kyoichi Nomura and Atsuro Chiba and Ryuji Kaji and Takashi Kanda and Kenichi Kaida and Ikeda, {Shu Ichi} and Tatsuro Mutoh and Ryo Yamasaki and Hiroshi Takashima and Makoto Matsui and Kazutoshi Nishiyama and Gen Sobue and Susumu Kusunoki",

note = "Publisher Copyright: {\textcopyright} 2017 Peripheral Nerve Society",

year = "2017",

month = dec,

doi = "10.1111/jns.12234",

language = "English",

volume = "22",

pages = "433--439",

journal = "Journal of the Peripheral Nervous System",

issn = "1085-9489",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "4",

}

Yamagishi, Y, Suzuki, H, Sonoo, M, Kuwabara, S, Yokota, T, Nomura, K, Chiba, A, Kaji, R, Kanda, T, Kaida, K, Ikeda, SI, Mutoh, T, Yamasaki, R, Takashima, H, Matsui, M, Nishiyama, K, Sobue, G & Kusunoki, S 2017, 'Markers for Guillain-Barré syndrome with poor prognosis: a multi-center study', Journal of the Peripheral Nervous System, vol. 22, no. 4, pp. 433-439. https://doi.org/10.1111/jns.12234

TY - JOUR

T1 - Markers for Guillain-Barré syndrome with poor prognosis

T2 - a multi-center study

AU - Yamagishi, Yuko

AU - Suzuki, Hidekazu

AU - Sonoo, Masahiro

AU - Kuwabara, Satoshi

AU - Yokota, Takanori

AU - Nomura, Kyoichi

AU - Chiba, Atsuro

AU - Kaji, Ryuji

AU - Kanda, Takashi

AU - Kaida, Kenichi

AU - Ikeda, Shu Ichi

AU - Mutoh, Tatsuro

AU - Yamasaki, Ryo

AU - Takashima, Hiroshi

AU - Matsui, Makoto

AU - Nishiyama, Kazutoshi

AU - Sobue, Gen

AU - Kusunoki, Susumu

PY - 2017/12

Y1 - 2017/12

N2 - Guillain-Barré syndrome (GBS) is an acute monophasic neuropathy. Prognostic tools include the modified Erasmus GBS outcome score (mEGOS), Erasmus GBS respiratory insufficiency score (EGRIS), and the increase in serum IgG levels (ΔIgG) 2 weeks after intravenous immunoglobulin (IVIg) treatment. Given that proportions of GBS subtypes differ between Western countries and Japan, the usefulness of these tools in Japan or other countries remains unknown. We enrolled 177 Japanese patients with GBS from 15 university hospitals and retrospectively obtained mEGOS and EGRIS for all and ΔIgG status for 79 of them. High mEGOS scores on admission or on day 7 were significantly associated with poorer outcomes (unable to walk independently at 6 months). High EGRIS scores (≥5 points) were associated with an increased risk for mechanical ventilation. Patients with ΔIgG <1,108 mg/dl had significantly poorer outcomes. We suggest that mEGOS, EGRIS, and ΔIgG in GBS are clinically relevant in Japan.

AB - Guillain-Barré syndrome (GBS) is an acute monophasic neuropathy. Prognostic tools include the modified Erasmus GBS outcome score (mEGOS), Erasmus GBS respiratory insufficiency score (EGRIS), and the increase in serum IgG levels (ΔIgG) 2 weeks after intravenous immunoglobulin (IVIg) treatment. Given that proportions of GBS subtypes differ between Western countries and Japan, the usefulness of these tools in Japan or other countries remains unknown. We enrolled 177 Japanese patients with GBS from 15 university hospitals and retrospectively obtained mEGOS and EGRIS for all and ΔIgG status for 79 of them. High mEGOS scores on admission or on day 7 were significantly associated with poorer outcomes (unable to walk independently at 6 months). High EGRIS scores (≥5 points) were associated with an increased risk for mechanical ventilation. Patients with ΔIgG <1,108 mg/dl had significantly poorer outcomes. We suggest that mEGOS, EGRIS, and ΔIgG in GBS are clinically relevant in Japan.

KW - EGRIS

KW - Guillain-Barré syndrome

KW - mEGOS

KW - prognostic marker

UR - http://www.scopus.com/inward/record.url?scp=85037710422&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037710422&partnerID=8YFLogxK

U2 - 10.1111/jns.12234

DO - 10.1111/jns.12234

M3 - Article

C2 - 28833828

AN - SCOPUS:85037710422

SN - 1085-9489

VL - 22

SP - 433

EP - 439

JO - Journal of the Peripheral Nervous System

JF - Journal of the Peripheral Nervous System

IS - 4

ER -

Markers for Guillain-Barré syndrome with poor prognosis: a multi-center study

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this